Opinion statement
-
Identification and treatment of the underlying risk factors for stroke reduce the potential for additional strokes; therefore, a thorough search for treatable risk factors is justified. Because some risk factors can have a cumulative effect, even children with known risk factors for stroke sometimes need to be evaluated for other conditions. Cerebral angiography is often helpful; I recommend angiography in any child with an unexplained infarction or hemorrhage. Angiography is especially important in children with intraparenchymal hemorrhage because more than one third of such children will prove to have some type of potentially treatable congenital vascular anomaly such as an arteriovenous malformation (AVM) or aneurysm.
-
The evidence that periodic blood transfusion effectively prevents cerebral infarction due to sickle cell disease is compelling. Transfusions apparently must be continued indefinitely to maintain the reduction of stroke risk, and without iron chelation, chronic transfusion eventually results in severe iron toxicity and, most likely, death, so the decision to begin transfusion is not an easy one. Measurement of the time-averaged mean flow velocity in the large cerebral vessels with transcranial Doppler (TCD) is highly predictive of stroke risk in these children, enough to justify its routine use in screening patients with sickle cell disease for stroke risk. I believe that patients with sickle cell disease should be offered chronic transfusion after an initial large-vessel stroke or when the TCD results suggest a high risk of stroke. The family must be made aware of the serious complications of chronic transfusion and the importance of complying with chelation once it is started.
-
There are no controlled clinical trials to guide the use of anticoagulants, antiplatelet agents, or thrombolytic agents in children, although these drugs are being used more and more often in pediatric patients. For the most part, our approach has been adapted from our experience with adults. Heparin followed by warfarin is often used for sinovenous thrombosis and for arterial dissection. I also suggest long-term anticoagulation for children with coagulopathy or a high risk of embolism due to congenital or acquired cardiac disease. It is reasonable to use a thrombolytic agent in children with an acute infarction; because few children present soon enough after the onset of symptoms, however, thrombolysis is infrequently used.
-
Aspirin is used more than other antiplatelet agents in children, largely because of years of experience with aspirin and the lack of evidence that other agents are more effective. Despite its frequent use, there are no unequivocal indications for the use of aspirin in children. Aspirin is often started empirically in children suspected to be at substantial risk for additional ischemic stroke but whose risk is ill defined, an approach not too dissimilar from that often used in adult patients. Although the risk of Reye’s syndrome in a child taking daily aspirin for stroke prevention is a common concern, I know of no published examples of children who developed Reye’s syndrome while taking prophylactic aspirin. This apparently low risk must be weighed against the often-considerable risk of ischemic stroke that could be reduced by the use of daily aspirin. In situations such as vasculopathy or infarction of unknown cause, the small risk of Reye’s syndrome seems acceptable.
Similar content being viewed by others
References and Recommended Reading
Roach ES, Riela AR: Pediatric Cerebrovascular Disorders, edn 2. New York: Futura; 1995.
Riela AR, Roach ES: Etiology of stroke in children. J Child Neurol 1993, 8:201–220.
Brower MC, Rollins N, Roach ES: Basal ganglia and thalamic infarction in children. Etiology and clinical features. Arch Neurol 1996, 53:1252–1256.
Al-Jarallah M, Al-Rifai T, Riela AR, Roach ES: Spontaneous intraparenchymal hemorrhage in children: a study of 68 patients. J Child Neurol 2000, 15:284–289.
Adelman LS, Doe FD, Sarnat HB: Bilateral dissecting aneurysms of the internal carotid arteries. Acta Neuropathol 1974, 29:93–97.
Lannuzel A, Moulin T, Amsallem D, et al.: Vertebral artery dissection following a judo session: a case report. Neuropediatrics 1994, 25:106–108.
Schievink WI, Mokri B, Piepgras DG: Spontaneous dissections of the cervicocephalic arteries in childhood and adolescence. Neurology 1994, 44:1607–1612.
Balkaran B, Char G, Morris JS, et al.: Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 1992, 120:360–366.
Kinney TR, Sleeper LA, Wang WC, et al.: Silent cerebral infarctions in sickle cell anemia: a risk factor analysis. Pediatrics 1999, 103:640–645.
Van Hoff J, Ritchey AK, Shaywitz BA: Intracranial hemorrhage in children with sickle cell disease. Am J Dis Child 1985, 139:1120–1123.
Ohene-Frempong K, Weiner SJ, Sleeper LA, et al.: Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998, 91:288–294.
Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR: Serial CT scanning in childhood tuberculous meningitis: prognostic features in 198 cases. J Child Neurol 1995, 10:320–329.
Kamholz J, Tremblay G: Chickenpox with delayed contralateral hemiparesis caused by cerebral angiitis. Ann Neurol 1985, 18:358–360.
Bodensteiner JB, Hille MR, Riggs JE: Clinical features of vascular thrombosis following varicella. Am J Dis Child 1992, 146:100–102.
Silverstein FS, Brunberg JA: Postvaricella basal ganglia infarction in children. Am J Neuroradiol 1995, 16:448–452.
Caekebeke JFV, Peters ACB, Vandvik B, et al.: Cerebral vasculopathy associated with primary varicella infection. Arch Neurol 1990, 47:1033–1035.
Kovacs SO, Kuban K, Strand R: Lateral medullary syndrome following varicella infection. Am J Dis Child 1993, 147:823–825.
Sebire G, Meyer L, Chabrier S: Varicella as a risk factor for cerebral infarction in childhood: a case-control study. Ann Neurol 1999, 45:679–680. This recent case-control study offers the best evidence so far that varicella is a risk factor for stroke in children. Seven of 11 children (64%) with idiopathic ischemic stroke had varicella during the 9 months before their stroke, compared to only 4 of the 44 children (9%) in the control group.
Chabrier S, Rodesch G, Lasjaunias P, et al.: Transient cerebral arteriopathy: a disorder recognized by serial angiograms in children with stroke. J Child Neurol 1998, 13:27–32.
Mitchell WG, Fishman LS, Miller JH, et al.: Stroke as a late sequela of cranial irradiation for childhood brain tumors. J Child Neurol 1991, 6:128–133.
Aylett SE, Britton JA, De Sousa CMCP: Down syndrome and moyamoya disease: presentation with subarachnoid hemorrhage. Pediatr Neurol 1996, 14:259–261.
Eyster ME, Gill FM, Blatt PM, et al.: Central nervous system bleeding in hemophiliacs. Blood 1978, 51:1179–1188.
Andes WA, Wulff K, Smith WB: Head trauma in hemophilia: a prospective study. Arch Intern Med 1984, 144:1981–1983.
Michelson AD, Bovill E, Andrew M: Antithrombotic therapy in children. Chest 1995, 108:506S-522S.
Andrew M, deVeber G: Pediatric Thromboembolism and Stroke Protocols. Hamilton, Ontario: B.C. Decker Inc.; 1997:1–63.
Massicotte P, Adams M, Marzinotta V, et al.: Low molecular weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996, 128:313–318.
Khamashta MA: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995, 332:993–997.
Peters LJ, Wiener GJ, Gilliam J, et al.: Reye’s syndrome in adults: a case report and review of the literature. Arch Intern Med 1986, 146:2401–2403.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for ischemic stroke. N Engl J Med 1995, 333:1581–1587.
Leaker M, Massicotte MP, Brooker L, Andrew M: Thrombolytic therapy in pediatric patients: a comprehensive review of the literature. Thromb Haemost 1996, 76:132–134.
Horowitz M, Purdy P, Unwin H, et al.: Treatment of dural sinus thrombosis using selective catheterization and urokinase. Ann Neurol 1995, 38:58–67.
Griesemer DA, Theodorou AA, Berg RA, Spera TD: Local fibrinolysis in cerebral venous thrombosis. Pediatr Neurol 1994, 10:78–80.
Adams RJ, McKie VC, Hsu L, et al.: Stroke prevention trial in sickle cell anemia (“STOP”): study results. N Engl J Med 1998, 339:5–11. This multicenter randomized controlled clinical trial demonstrated conclusively that periodic blood transfusion reduces the risk of ischemic stroke due to sickle cell disease in patients at higher risk (determined by TCD).
Cohen AR, Martin MB, Silber JH, et al.: A modified transfusion program for prevention of stroke in sickle cell disease. Blood 1992, 79:1657–1661. This study of 15 patients with sickle cell disease suggests that a less intense transfusion program designed to maintain the sickle hemoglobin near 50% could prevent most infarctions, with a lower risk of iron toxicity.
Wang WC, Kovnar EH, Tonkin IL, et al.: High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr 1991, 118:377–382.
Matsushima T, Inoue T, Suzuki SO, et al.: Surgical treatment of moyamoya disease in pediatric patients—comparison between the results of indirect and direct revascularization procedures. Neurosurgery 1992, 31:401–405.
Yamada I, Matsushima Y, Suzuki S: Childhood moyamoya disease before and after encepalo-duroarterio-synangiosis: an angiographic study. Neuroradiology 1992, 34:318–322.
Fukui M: Current state of study on moyamoya disease in Japan. Surg Neurol 1997, 47:138–143. Of the 821 patients from the Japanese moyamoya registry summarized in this report, 23% were treated without surgery; no significant differences in outcome were noted between the medically and the surgically treated groups.
Ikezaki K: A rational approach to treatment of moyamoya disease in childhood. J Child Neurol 2000, 15:350–356.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roach, E.S. Stroke in children. Curr Treat Options Neurol 2, 295–303 (2000). https://doi.org/10.1007/s11940-000-0047-5
Issue Date:
DOI: https://doi.org/10.1007/s11940-000-0047-5